In TO339 transmitted at 1617e today, an error occurred in the first paragraph. The timing of the live teleconference should have read: "9:00 am
MDT" and not "9:00 pm MDT". Corrected copy follows:
Resverlogix Notice of Conference Call & Webcast
TSX Exchange Symbol: RVX
CALGARY, May 1 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that it will host a live teleconference on May 8, 2008 at 9:00 am MDT to provide a year-end update on both the science and the business aspects of the Company. Following the presentation there will be a live question and answer session.
The webcast can be accessed at the following link:
http://services.choruscall.com/links/resverlogix0800508.html or on
Resverlogix's website at: http://www.resverlogix.com.
Participants can also dial in for the conference call:
Dial information is as follows:
International Dial In: 1 604 638 5340
North America Toll Free: 1 800 319 4610
The webcast will be available on the Resverlogix website for replay for a period of 10 days after the event.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary
focus which is to develop novel small molecules that enhance ApoA-I. These
vital therapies address the grievous burden of atherosclerosis and other
important diseases such as acute coronary syndrome, diabetes, Alzheimer's
and other vascular disorders. The Company's secondary focus is TGF-Beta
Shield(TM), a program that aims to address burgeoning grievous diseases,
such as cancer and fibrosis. Resverlog
|SOURCE Resverlogix Corp.|
Copyright©2008 PR Newswire.
All rights reserved